D. W. LEE ET AL: "Current concepts in the diagnosis and management of cytokine release syndrome", BLOOD, vol. 124, no. 2, 29 May 2014 (2014-05-29), US, pages 188 - 195, XP055313556, ISSN: 0006-4971, DOI: 10.1182/blood-2014-05-552729 (B1)

XU XIAO-JUN ET AL: "Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells", CANCER LETTERS, NEW YORK, NY, US, vol. 343, no. 2, 16 October 2013 (2013-10-16), pages 172 - 178, XP028814569, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2013.10.004 (B1)

DANG KEVIN ET AL: "Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 6, 1 June 2021 (2021-06-01), pages e002488, XP55906546, Retrieved from the Internet <URL:https://jitc.bmj.com/content/9/6/e002488> DOI: 10.1136/jitc-2021-002488 (B1)

GÖKBUGET NICOLA ET AL: "Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 131, no. 14, 5 April 2018 (2018-04-05), pages 1522 - 1531, XP086510922, ISSN: 0006-4971, [retrieved on 20201104], DOI: 10.1182/BLOOD-2017-08-798322 (B1)

LI JI ET AL: "Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 508, 4 September 2019 (2019-09-04), pages eaax8861, XP055786539, ISSN: 1946-6234, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/scitransmed/11/508/eaax8861.full.pdf> DOI: 10.1126/scitranslmed.aax8861 (B1)

LI JI ET AL: "CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 508, 4 September 2019 (2019-09-04), pages eaax8861, XP55786539, ISSN: 1946-6234, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/scitransmed/11/508/eaax8861.full.pdf> DOI: 10.1126/scitranslmed.aax8861 (B1)

LUKE JASON J ET AL: "Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 2, 27 April 2021 (2021-04-27), pages e002015, XP055918532, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898862/pdf/jitc-2020-002015.pdf> DOI: 10.1136/jitc-2020-002015 (B1)

SHIMABUKURO-VORNHAGEN ALEXANDER ET AL: "Cytokine release syndrome", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 6, no. 1, 15 June 2018 (2018-06-15), XP055918827, Retrieved from the Internet <URL:http://link.springer.com/content/pdf/10.1186/s40425-018-0343-9.pdf> DOI: 10.1186/s40425-018-0343-9 (B1)

US-A1- 2019 336 504 (B1)

WO-A1-2019/133747 (B1)

WO-A2-2017/097723 (B1)

WO-A2-2019/224718 (B1)

XIAOYING CHEN ET AL: "A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities", CTS - CLINICAL AND TRANSLATIONAL SCIENCE, vol. 12, no. 6, 26 July 2019 (2019-07-26), US, pages 600 - 608, XP55769696, ISSN: 1752-8054, DOI: 10.1111/cts.12662 (B1)

XIAOYING CHEN ET AL: "Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells", CTS - CLINICAL AND TRANSLATIONAL SCIENCE, vol. 12, no. 6, 26 July 2019 (2019-07-26), US, pages 600 - 608, XP055769696, ISSN: 1752-8054, DOI: 10.1111/cts.12662 (B1)

D. W. LEE ET AL: "Current concepts in the diagnosis and management of cytokine release syndrome", BLOOD, vol. 124, no. 2, 29 May 2014 (2014-05-29), US, pages 188 - 195, XP55313556, ISSN: 0006-4971, DOI: 10.1182/blood-2014-05-552729 (B1)